featured

Latest stories

The problem for nutriceuticals

You wrote to me to suggest that supplements work…. but this highlights a problem for nutriceutical studies. There is no patent protection to be had and so pharmaceutical companies are not willing to spend big bucks to do a study where anyone can come along and sell the product without any outlay for drug development. So someone says let’s do a prevention study with supplement X…...

MS Awards…Want a gong?

MS Brain Health Awards 2022 – global launchMS Brain Health is launching an annual series of awards to highlight the global impact of MS Brain Health and showcase some examples of the ongoing progress in this area. The first MS Brain Health Awards ceremony will celebrate the work of many healthcare professionals, MS societies and people with MS in addressing the...

What is the cancer risk with MS Disease-modifying treatments?

This question comes up time and again with MS treatments and probably is one of the most important negative selection choices secondary to PML for DMTs in MS. Every time a new drug is presented to the clinical community, the cancer stats are heavily scrutinised. For example, with ocrelizumab the greater number of breast cancers in the treated arm versus placebo impacted on who ultimately received...

Sipping siponimod and other SIPs

Go grab a cup of tea There are a group of drugs used in MS called Sphingosine-1-phosphate receptor modulators. These are known as “the imods”. Here, mod means modulator” and “i” means immune so the immune modulators have been shortened to “imod”. Some people get paid a load of cash to come up with drug names and they have come up with interesting ones...

Will the NIHR give us the chance to test AI-assisted MRI in clinical practice?

I recently posted on the promises of AI-assisted MRI in routine follow-up of pwMS and mentioned that we’re applying, together with colleagues based in Nottingham and a commercial leader in the field (icometrix), for an NIHR award to see whether such an approach can indeed result in better “quality, efficiency and equity in the NHS care of multiple sclerosis” (from the title of...

Dieting.

I think I just wrote that I wouldnot write anything about diets, but I have been challenged You said “I know diet is seen as quackery on this blog. However it seams to be actually showing evidence of neuroprotection more than any of the drugs trialed so far”. I would argue not at all, ProfG may have talked about them, indeed he has just sent me a book on diets as has DoctorLove...

Saloua Mrabet – 2022 MENACTRIMS fellow

Hello !!                                                                                                I am Saloua Mrabet, the new MENACTRIMS fellow. I am an MSologist from Tunis, Tunisia. I am interested in Multiple Sclerosis and related inflammatory diseases and especially some hot topics in this field: HSCT, highly active DMT, Ethnicity and MS, genetics of MS and Women’s Issues in MS.  Happy...

Difficulty is seeing Saving Nerves with Statins

Statins are agents used to reduce cholesterol. When used in a UK trial called MS-STAT they found that brain loss was slowed and suggested there was a benefical effect suggesting that nerves loss is inhibited by statins. “High-dose simvastatin reduced the annualised rate of whole-brain atrophy compared with placebo, and was well tolerated and safe”. So we now have MS-STAT2 on the go...

What influences if your CSF Neurofilament comes down?

Many of you will have now heard about neurofilament light chain (NfL) measurements. You may even have a record of your last reading. A large bulk of the published literature on NfL now is on blood NfL, because it is easier to obtain (less invasive) allowing you to carry out large scale analyses. However, sampling the CSF has the added advantage that it is close to the brain and is therefore...

Translate

Categories

Recent Posts

Recent Comments

Archives